Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.52 |
| ▸ | CTRB1 | P17538 | 3/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | APP | P05067 | 3/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.42 |
| ▸ | CTSS | P25774 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8908191 | 1.00 | ATM (0.52) | ATMCTRB1CYP3A4MAPK1APP | |
| SCHEMBL8908134 | 0.86 | CTSG (0.50) | ATMCTRB1CTSS | |
| SCHEMBL7440669 | 0.85 | CTRB1 (0.52) | ATMCTRB1CYP3A4MAPK1NPC1 | |
| SCHEMBL753184 | 0.85 | CTRB1 (0.52) | ATMCTRB1CYP3A4MAPK1NPC1 | |
| SCHEMBL753199 | 0.85 | CTRB1 (0.52) | ATMCTRB1CYP3A4MAPK1NPC1 | |
| SCHEMBL890195 | 0.84 | CTRB1 (0.51) | ATMCTRB1CYP3A4MAPK1NPC1 | |
| SCHEMBL12979843 | 0.84 | CTRB1 (0.51) | ATMCTRB1CYP3A4MAPK1NPC1 | |
| SCHEMBL890231 | 0.84 | CTRB1 (0.51) | ATMCTRB1CYP3A4MAPK1NPC1 | |
| SCHEMBL8908068 | 0.81 | CTSS (0.45) | ATMCYP3A4CTSS | |
| SCHEMBL888811 | 0.81 | CTRB1 (0.52) | ATMCTRB1CYP3A4MAPK1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8673954-B2 | Benzimidazole derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2014-03-18 | — | — | US | disclosed |
| US-20120076756-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2012-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120076756-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | EIF2AK2, ZC3HAV1, HAVCR2 | ATM 4578/4885CTRB1 1254/4885CYP3A4 56/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.